Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures

Arbutus Biopharma Corp

Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.
Net loss $33.5M for 2025 vs $69.9M in 2024; revenue $14.1M, up from $6.2M.
Moderna settlement: $950M noncontingent due July 2026; contingent $1.3B on 1498 ruling. Arbutus gets 20% of noncontingent after costs.
Two additional imdusiran Phase 2a patients achieved functional cure for chronic HBV, total 10 to date.
Company evaluating return of capital to shareholders in Q3 2026 after Moderna payment receipt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arbutus Biopharma Corp reported the fourth quarter and year ended December 31, 2025 results: revenue $14.1 million.

Period: the fourth quarter and year ended December 31, 2025
Revenue: $14.1 million
Result: reported results

Exact text from the filing

one-time payments related to its restructuring efforts. This was partially offset by $5.5 million of proceeds from the exercise of stock options. Revenue Total revenue was $14.1 million for the year ended December 31, 2025, compared to $6.2 million for the same period in 2024. The increase of $7.9 million was due to the recognition of all previously-deferred

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-26-001838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.